Literature DB >> 24756144

Increasing use of advanced radiation therapy technologies in the last 30 days of life among patients dying as a result of cancer in the United States.

B Ashleigh Guadagnolo1, Kai-Ping Liao2, Sharon H Giordano2, Linda S Elting2, Thomas A Buchholz2, Ya-Chen Tina Shih2.   

Abstract

PURPOSE: We sought to analyze trends in radiation therapy (RT) technology use and costs in the last 30 days of life for patients dying as a result of cancer.
METHODS: We used the Surveillance, Epidemiology, and End Results (SEER) -Medicare and Texas Cancer Registry-Medicare databases to analyze claims data for 13,488 patients dying as a result of lung, breast, prostate, colorectal, melanoma, and pancreas cancers from 2000 to 2009. Logistic regression modeling was used to conduct adjusted analyses regarding influence of demographic, clinical, and health services variables on receipt of types of RT. Costs were calculated in 2009 US dollars.
RESULTS: The proportion of patients treated with two-dimensional RT decreased from 74.9% of those receiving RT in the last 30 days of life in 2000 to 32.7% in 2009 (P < .001). Those receiving three-dimensional RT increased from 27.2% in 2000 to 58.5% in 2009 (P < .001). The proportion of patients treated with intensity-modulated radiation therapy in the last 30 days of life increased from 0% in 2000 to 6.2% in 2009 (P < .001), and those undergoing stereotactic radiosurgery increased from 0% in 2000 to 5.0% in 2009 (P < .001). The adjusted mean costs of per-patient RT services delivered in the last 30 days of life were higher in the years 2007 to 2009.
CONCLUSION: Among patients receiving RT in the last month of life, there was a shift away from the simplest technique toward more advanced RT technologies. Studies are needed to ascertain whether these technology shifts improve palliative outcomes and quality of life for patients dying as a result of cancer who receive RT services.
Copyright © 2014 by American Society of Clinical Oncology.

Entities:  

Mesh:

Year:  2014        PMID: 24756144      PMCID: PMC4094648          DOI: 10.1200/JOP.2013.001348

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  31 in total

1.  The sources of the SGR "hole".

Authors:  Ali Alhassani; Amitabh Chandra; Michael E Chernew
Journal:  N Engl J Med       Date:  2011-12-21       Impact factor: 91.245

Review 2.  Stereotactic body radiation for the spine: a review.

Authors:  Sheema Chawla; Michael C Schell; Michael T Milano
Journal:  Am J Clin Oncol       Date:  2013-12       Impact factor: 2.339

3.  Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients.

Authors:  Carrie N Klabunde; Linda C Harlan; Joan L Warren
Journal:  Med Care       Date:  2006-10       Impact factor: 2.983

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

5.  Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation.

Authors:  Aileen B Chen; Bridget A Neville; David J Sher; Kun Chen; Deborah Schrag
Journal:  J Clin Oncol       Date:  2011-05-02       Impact factor: 44.544

6.  Can physicians accurately predict survival time in patients with metastatic cancer? Analysis of RTOG 97-14.

Authors:  William F Hartsell; Michelle Desilvio; Deborah Watkins Bruner; Charles Scarantino; Robert Ivker; Mack Roach; John Suh; William F Demas; Benjamin Movsas; Ivy A Petersen; Andre A Konski
Journal:  J Palliat Med       Date:  2008-06       Impact factor: 2.947

Review 7.  A systematic review of physicians' survival predictions in terminally ill cancer patients.

Authors:  Paul Glare; Kiran Virik; Mark Jones; Malcolm Hudson; Steffen Eychmuller; John Simes; Nicholas Christakis
Journal:  BMJ       Date:  2003-07-26

8.  Dosimetric and clinical impact of 3D vs. 2D planning in palliative radiotherapy for bone metastases.

Authors:  Kathy Pope; David Fitzpatrick; Andrew Potter; Michael Holwell; Lisa Wang; Michelle Lau; Wilfred Levin; Michael McLean; Laura Zurawel Balaura; Andrea Bezjak; Rebecca K S Wong
Journal:  Support Care Cancer       Date:  2013-03-16       Impact factor: 3.603

9.  A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients.

Authors:  Carrie N Klabunde; Julie M Legler; Joan L Warren; Laura-Mae Baldwin; Deborah Schrag
Journal:  Ann Epidemiol       Date:  2007-05-25       Impact factor: 3.797

10.  The role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer: evidence for changing paradigms.

Authors:  Max Dahele; Suresh Senan
Journal:  Cancer Res Treat       Date:  2011-06-30       Impact factor: 4.679

View more
  4 in total

1.  Variation in Use of High-Cost Technologies for Palliative Radiation Therapy by Radiation Oncologists.

Authors:  Aileen B Chen; Jiangong Niu; Angel M Cronin; Ya-Chen Tina Shih; Sharon Giordano; Deborah Schrag
Journal:  J Natl Compr Canc Netw       Date:  2021-02-12       Impact factor: 12.693

2.  Interrupted Time-Series Analysis of Stereotactic Radiosurgery for Brain Metastases Before and After the Affordable Care Act.

Authors:  Hind A Beydoun; Shuyan Huang; May A Beydoun; Shaker M Eid; Alan B Zonderman
Journal:  Cureus       Date:  2022-01-17

3.  Prognostication in palliative radiotherapy-ProPaRT: Accuracy of prognostic scores.

Authors:  Marco Maltoni; Emanuela Scarpi; Monia Dall'Agata; Simona Micheletti; Maria Caterina Pallotti; Martina Pieri; Marianna Ricci; Antonino Romeo; Maria Valentina Tenti; Luca Tontini; Romina Rossi
Journal:  Front Oncol       Date:  2022-08-16       Impact factor: 5.738

4.  The challenge of sustainability in healthcare systems: cost of radiotherapy in the last month of life in an Italian cancer center.

Authors:  Romina Rossi; Valentina Danesi; Ilaria Massa; William Balzi; Antonino Romeo; Flavia Foca; Oriana Nanni; Marco Maltoni; Mattia Altini
Journal:  Support Care Cancer       Date:  2020-09-28       Impact factor: 3.603

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.